

Jonas Jarvius to step down as CEO of Q-linea during 2024

Jonas Jarvius has informed Q-linea AB:s (publ) (OMX: QLINEA) board of directors that he plans to step down as CEO before summer 2024 to take over as CEO of a US based life science company. Three of the major shareholders of Q-linea (69% of the shares) has informed the Board of Directors of its intention to support Jonas Jarvius as a new board member in 2024.

“It has truly been a privilege to work for Q-linea for over 15 years. I am pleased and honored that the major owners would like me to continue to contribute to the future development of Q-linea in a new role. I am proud of what we have accomplished so far, we have built a strong commercial foundation and I hope to see ASTar enter the US market before I step down. I look forward to seeing all the good Q-linea will do for patients with severe infections”, said Jonas Jarvius, CEO of Q-linea.

“Jonas has been instrumental in the development of Q-linea. The board and I will miss him as CEO and it is regrettable that he steps down. At the same time we see that his long experience and solid background can add valuable perspectives to the work of the board. Q-linea has built a strong foundation and now our search for a new CEO that can take the company through the next stage of commercialization begins,” said Erika Kjellberg Eriksson, Chairman of the board.

For more information, please contact:

Erika Kjellberg Eriksson, Chairman of the board, Q-linea AB
Erika.Kjellberg@nxt2b.com

Jonas Jarvius, CEO, Q-linea AB
Jonas.Jarvius@qlinea.com
+46 (0) 70-323 77 60

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

This information is information that Q-linea is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-09-07 08:43 CEST.

Attachments

[Jonas Jarvius to step down as CEO of Q-linea during 2024](#)